预约演示
更新于：2025-04-17
Aceclofenac
醋氯芬酸
更新于：2025-04-17
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 西班牙 (1993-05-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H13Cl2NO4 |
InChIKeyMNIPYSSQXLZQLJ-UHFFFAOYSA-N |
CAS号89796-99-6 |
关联
43
项与 醋氯芬酸 相关的临床试验CTRI/2024/11/077314
A post approval observational study to assess the impaCt Of fixed dose coMbination of Trypsin: Chymotrypsin+ Aceclofenac + Paracetamol In Outpatient SEttings of India (COMPOSE I) - Compose I
CTRI/2024/11/077228
A Comparative Evaluation of The Effect of Low-Level LASER Therapy, LASER-Activated Irrigation and Preoperative Aceclofenac on Post Endodontic Pain After Single Visit Root Canal Treatment - A Randomized Controlled Trial. - NIL
CTR20243256
醋氯芬酸片（100mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 醋氯芬酸 相关的临床结果
登录后查看更多信息
100 项与 醋氯芬酸 相关的转化医学
登录后查看更多信息
100 项与 醋氯芬酸 相关的专利（医药）
登录后查看更多信息
1,896
项与 醋氯芬酸 相关的文献（医药）2025-02-01JOURNAL OF MOLECULAR STRUCTURE
Drug-amino acid interaction: Molecular dynamics in aqueous medium using time domain reflectometry
作者: Alwaleedy, Suad ; Narwade, Pallavi ; Kumbharkhane, Ashok C. ; Karale, Ravikant R. ; Al-Hamdani, Saeed Mohammed ; Kamble, Savita ; Sarode, Arvind V.
Present work reports dielec. response of the non-steroidal anti-inflammatory drug (NSAID) aceclofenac in aqueous valine solutions at various concentrations and temperatures (278.15 K-298.15 K) in the frequency range of 0.01 GHz to 30 GHz using Time-domain reflectometry (TDR) technique.The frequency dependent complex dielec. permittivity has been analyzed by Harviliak-Negami equation.Debye model is used for the description of complex dielec. permittivity spectra ε*(ν).The structural and dynamical properties of water has been investigated at different concentrations of valine and aceclofenac using dielec. as well as thermodn. parameters that includes static dielec. constant (ε0), relaxation time (τ0), Kirkwood correlation factor (g), free energy of activation (ΔF), entropy of activation (ΔS), and enthalpy of activation (ΔH).Towards the measured low temperature and high concentrations of Valine and Aceclofenac (ACF), static dielec. constant (ε0) was found to be increasing.This could be due to increased effective dipole-dipole parallel alignment and can be confirmed by the increasing values of correlation factor (g > 1).The dipole-dipole interaction between Drug-Amino acid resulted in increased dielec. relaxation time (τ0) of system due to increased steric hindrance for the rotation of dipoles.The free energy of activation was found to be in the range of 2.22 and 2.58 Kcal mol-1.The entropy is more neg. at high concentration suggesting more ordered structure.The slope of log (Tτ0) vs. 1000/T gives the value of enthalpy (ΔH).
2025-01-02Expert Opinion On Drug Safety
Risk of drug-induced delirium in older patients- a pharmacovigilance study of FDA adverse event reporting system database
Article
作者: Li, Jiayu ; Zhou, Ying ; Jia, Boying ; Zhou, Shuang ; Wan, Liyan ; Cui, Yimin
BACKGROUND:
Drug-induced delirium is known risk factors associated with increased morbidity and mortality in older patients. The objective was to evaluate the risk of drug-related delirium in older patients based on the FDA Adverse Event Reporting System (FAERS).
RESEARCH DESIGN AND METHODS:
Delirium reports in older patients (age ≥65) extracted from the FAERS database using Open Vigil 2.1. The reported odds ratio and the proportional reported ratio were calculated to detect the adverse reaction signal of delirium. Combined with published evidence, suspected drugs were categorized as known, possible, or new potential delirium-risk-increasing drugs.
RESULTS:
Of the 130,885 reports (including 28,850 delirium events and 1,857 drugs) analyzed for this study, 314 positive signal drugs were detected. Positive signal drugs are mainly concentrated on the drug of nervous system, cardiovascular system , alimentary tract and metabolism and anti-infectives for systemic use. Of the positive signal drugs, 26.11% (82/314) were known delirium-risk increasing drugs, 44.90% (141/314) were possible and 28.98% (91/314) were new potential.
CONCLUSION:
Drug-induced delirium risk is prevalent in older patients, according to the FAERS. The risk level of drug-induced delirium should be taken into account to optimize drug therapy in clinical practice.
2025-01-01Recent Advances in Inflammation & Allergy Drug Discovery
Formulation and Evaluation of Microsponges-loaded Transdermal Gel for the Management of Osteoarthritis
Article
作者: Mittal, Vishnu ; Kriplani, Priyanka ; Sharma, Anjali ; Sen, Shiwani ; Malhotra, Hitesh
Background::
Osteoarthritis (OA) stands as the most widespread form of arthritis,
representing a primary source of pain and functional impairment among the elderly. It is often
referred to as a degenerative joint disease. OA is more than just wear and tear; it is an aberrant
remodelling of joint tissues prompted by a deluge of inflammatory mediators released within the
compromised joint. This disease affects 15 million people in India annually.
Objective::
Aceclofenac is a COX-2 inhibitor that has anti-inflammatory activity. However, aceclofenac
has a short mean plasma elimination half-life and poor water solubility. It requires frequent
dosing, which has been linked to a number of negative side effects, including bleeding
and gastrointestinal irritation. A potential solution to this problem is the transdermal administration
of aceclofenac using microsponges. In order to have a synergistic effect along with the bioenhancer
effects, piperine was incorporated into the formulation.
Methods::
Microsponges were created using the quasi-emulsion solvent diffusion method. After
characterization, the prepared microsponges were incorporated into the Carbopol gel. The in
vivo study focused on evaluating the optimized formulation, F1.
Results::
All the prepared microsponge formulations underwent assessment based on parameters
including yield of production, entrapment efficiency, and in vitro drug release. The outcomes
indicated that batches ranging from F1 to F9 showed positive entrapment efficiency and in vitro
drug release. From 50.37% to 80.76 % and 71.18% to 91.8% and in vivo studies the results reveal
that the inflammatory cells in the best formulation Ace(B)group were reduced hence the
formulation's anti-inflammatory impact was achieved.
Conclusion::
The findings indicate that Formulation F1 exhibits superior entrapment and enhanced
drug release. The kinetics study suggests that the optimized formulation aligns well with
the Higuchi model and adheres to the Fickian transport drug release mechanism. Animal study
findings suggest that optimized formulation Ace(B)may possess ideal -anti-osteoarthritic activity
for osteoarthritic disease. Further clinical trials on humans may be conducted in order to
make the research fruitful for society.
100 项与 醋氯芬酸 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 平滑肌瘤 | 欧盟 | 2018-08-27 | |
| 平滑肌瘤 | 冰岛 | 2018-08-27 | |
| 平滑肌瘤 | 列支敦士登 | 2018-08-27 | |
| 平滑肌瘤 | 挪威 | 2018-08-27 | |
| 类风湿关节炎 | 英国 | 1996-04-08 | |
| 强直性脊柱炎 | 英国 | 1996-03-24 | |
| 骨关节炎 | 英国 | 1996-03-24 | |
| 风湿性疾病 | 西班牙 | - | 1993-05-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 120 | Aceclofenac 100 mg twice a day | 窪襯夢衊憲淵製壓窪廠(顧鹹憲鏇壓顧構選憲製) = Adverse events of therapy were mild and not require discontinuation of therapy 鹽淵遞蓋網艱鹽鑰衊範 (醖蓋積艱選構構築鹽網 ) | 积极 | 2020-08-20 | ||
N/A | - | NSAIDs | 網襯糧製觸選膚願襯繭(顧壓獵淵鬱廠網鹹獵構) = 齋範顧鑰鹽選鏇顧獵夢 鹽鑰築獵壓蓋願膚獵壓 (範醖艱鹹醖鏇夢鏇夢鏇, 1.7 ~ 3.1) | - | 2015-06-10 | ||
临床4期 | 143 | 蓋廠範襯襯製艱鹽衊餘(夢構壓淵顧鹽築願餘餘) = 製觸鑰鏇繭鏇窪選襯夢 蓋淵鏇願襯憲淵襯醖蓋 (網蓋鑰壓製糧窪鑰壓積, 14.17) 更多 | - | 2013-06-24 | |||
N/A | 200 | 衊積積選願窪膚築獵獵(網願醖淵鬱觸鏇廠繭築) = Adverse effects were noted in 3% of Aceclofenac treated OA patients and in 12% subjects treated with Diclofenac 遞艱願鏇繭齋積鏇築蓋 (窪製壓鹽糧艱範願顧網 ) | - | 2012-06-06 | |||
N/A | - | 齋艱鬱鹹築簾鏇鹹網製(餘糧醖構廠齋願鏇憲積) = 夢網糧艱簾廠鹹廠簾壓 構觸選獵衊範繭範膚網 (膚製蓋選獵憲顧餘淵淵 ) 更多 | 积极 | 2002-06-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用